title: Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects.
abstract: BACKGROUND
  Statins, particularly rosuvastatin, have recently become relevant in the setting of venous thrombosis. The objective of this study was to study the non-lipid lowering effects of rosuvastatin in venous thrombosis in mice with hyperlipidemia.
  
  
  METHODS
  An inferior vena cava ligation model of venous thrombosis in mice was utilized. Saline or 5mg/kg of rosuvastatin was administered by gavage 48hs previous to thrombosis. Blood, the inferior vena cava, thrombus, and liver were harvested 3, 6hours, and 2days post-thrombosis. Thrombus weight, inflammatory markers, and plasminogen activator inhibitor-1 expression and plasma levels were measured. Also, neutrophil migration to the IVC was assessed.
  
  
  RESULTS
  Rosuvastatin significantly decreased thrombus weight, plasminogen activator inhibitor-1 expression and plasma levels, expression of molecules related to the interleukin-6 pathway, and neutrophil migration into the vein wall.
  
  
  CONCLUSIONS
  This work supports the beneficial effects of rosuvastatin on venous thrombosis in mice with hyperlipidemia, due to its non-lipid lowering effects.
authors.affiliation: Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI 48103, USA.
authors.forename: K A
authors.initials: KA
authors.lastname: Patterson
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.forename: S K
authors.initials: SK
authors.lastname: Wrobleski
authors.forename: A E
authors.initials: AE
authors.lastname: Hawley
authors.forename: D A
authors.initials: DA
authors.lastname: Lawrence
authors.forename: T W
authors.initials: TW
authors.lastname: Wakefield
authors.forename: D D
authors.initials: DD
authors.lastname: Myers
authors.forename: J A
authors.initials: JA
authors.lastname: Diaz
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics; D002465:Cell Movement; D004195:Disease Models, Animal; D005464:Fluorobenzenes / Q000494:pharmacology*; D017353:Gene Deletion; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics; D007249:Inflammation / Q000473:pathology; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009504:Neutrophils / Q000166:cytology / Q000378:metabolism; D019007:P-Selectin / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D000068718:Rosuvastatin Calcium; D058258:Serpin E2 / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology*; D013927:Thrombosis / Q000473:pathology; D013997:Time Factors; D014682:Vena Cava, Inferior / Q000601:surgery; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D001057:Apolipoproteins E; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015850:Interleukin-6; D019007:P-Selectin; D011743:Pyrimidines; D058258:Serpin E2; C511869:Serpine2 protein, mouse; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium